

DISCLAIMER

This presentation contains certain statements that are forward-looking statements. They appear in a number of places throughout this presentation and include statements regarding the intentions, beliefs and/or current expectations of Smiths Group plc (the "Company") and its subsidiaries (together, the "Group") and those of their respective officers, directors and employees concerning, amongst other things, the results of operations, financial condition, liquidity, prospects, growth, strategies and the businesses operated by the Group. By their nature, these statements involve uncertainty since future events and circumstances can cause results and developments to differ materially from those anticipated. The forward-looking statements reflect knowledge and information available at the date of preparation of this presentation and, unless otherwise required by applicable law, the Company undertakes no obligation to update or revise these forward-looking statements. Nothing in this presentation should be construed as a profit forecast. The Company and its directors accept no liability to third parties. This presentation contains brands that are trademarks and are registered and/or otherwise protected in accordance with applicable law.

TODAY'S AGENDA



Chairman's address

Sir George Buckley, Chairman



Chief Executive's review

Andy Reynolds Smith, Chief Executive



Q&A

CHAIRMAN'S ADDRESS

SIR GEORGE BUCKLEY CHAIRMAN



INTRODUCTION





TRADING UPDATE

- Continuing Operations¹ underlying² revenue up 11% in Q1
- Smiths Medical underlying² revenue up 2% in Q1
- Outlook for the year reaffirmed

Continuing operations exclude Smiths Medical which is accounted for as 'discontinued operations - businesses held for distribution to owners', given the intended separation of Smiths Medical by the end of H1 CY2020

Underlying modifies headline performance to: adjust prior year to reflect an equivalent period of ownership for divested businesses; and exclude the effects of foreign exchange, acquisitions and supplemental sales for divested businesses

FY2020 OUTLOOK

- → A year of further progress
- → Growth H1 weighted
- Improved operational excellence and cash generation

BUILDING ON OUR STRATEGIC PROGRESS



UPDATE ON SEPARATION OF SMITHS MEDICAL



→ Key performance milestones achieved:


H2 return to growth - up 2%

Ongoing NPD including Large Volume Pump submission Medical CEO appointment











→ Good progress on Smiths Medical improvement plan

CREATING TWO STRONGER BUSINESSES


SMITHS - A LEADING INDUSTRIAL TECHNOLOGY COMPANY



SMITHS - A LEADING INDUSTRIAL TECHNOLOGY COMPANY



LEADING BUSINESSES IN ATTRACTIVE GROWING MARKETS



¹ % of revenue in top 3 leadership position

OPERATIONAL EXCELLENCE & INNOVATION

OPERATIONAL EXCELLENCE

- Working capital at 20% of sales -£150m opportunity
- Smiths Excellence System driving improvement across the Group



INNOVATION

Smiths
Detection CT
hand baggage
scanner

Digital Forge – accelerating our digital agenda

ESG-focused product development

John Crane Aura™ seal reduces methane emission









STRONG FINANCIAL PERFORMANCE¹











- 1 Continuing operations
- 2 Headline excludes non operating items as defined in note 3 of the accounts. Underlying modifies headline performance to: adjust prior year to reflect an equivalent period of ownership for divested businesses; and exclude the effects of foreign exchange, acquisitions and supplemental sales for divested businesses
- 3 Both FY2016 and FY2017 have been adjusted for the restructuring and pension administration costs that are now recorded as headline items for comparability and has all the central costs allocated to Continuing operations

DRIVING LONG-TERM, SUSTAINABLE VALUE





POLL VOTE RESOLUTIONS

- 1. Adoption of Annual Report FY2019
- 2. Approval of Directors' Remuneration Report
- Declaration of a final dividend
- 4. Re-election of Bruno Angelici as a director
- 5. Re-election of Olivier Bohuon as a director
- 6. Re-election of Sir George Buckley as a director
- 7. Re-election of Dame Ann Dowling as a director
- 8. Re-election of Tanya Fratto as a director
- 9. Re-election of William Seeger as a director
- 10. Re-election of Mark Seligman as a director
- 11. Re-election of John Shipsey as a director

- 12. Re-election of Andrew Reynolds Smith as a director
- 13. Re-election of Noel Tata as a director
- 14. Appointment of KPMG LLP as auditors
- 15. Auditors' remuneration
- 16. Authority to issue shares
- 17. Authority to disapply pre-emption rights
- 18. Additional authority to disapply pre-emption rights
- 19. Authority to make market purchases of shares
- 20. Authority to call general meetings on short notice
- 21. Authority to make political donations and expenditure

PROXY VOTES CAST

- → 313 million proxy votes cast
- → 78.92% of the issued share capital

POLL CLOSED

The final results of the poll will be announced and posted on our website shortly

